Solve FSHD
- Company typePrivate
- Founded2022
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
Solve FSHD firmographics
Firmographics- Name
- Solve FSHD
- Legal name
- SOLVE FSHD Holdings Ltd.
- Website
- https://solvefshd.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Solve FSHD industry classification
Industry- Product category
- Venture Philanthropy / FSHD Disease Research Funding
- NAICS
- Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
Keywords
Where Solve FSHD is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Solve FSHD business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Marketing or Sales, Others
Revenue model
- Venture Philanthropy / Charitable Grant Funding: SOLVE FSHD operates as a venture philanthropy organization funded by the Wilson family's $100 million USD commitment. The organization deploys capital through grants to academic researchers (up to $300,000 USD per grant, max 2 years, max 10% overhead), direct equity investments in biotech companies (e.g., $3M to Armatus Bio, up to $10M to Vita Therapeutics, $1M to miRecule), strategic co-development collaborations (Modalis, Transcripta Bio), and industry sponsorships of the XPRIZE Healthspan FSHD Bonus Prize. The organization does not generate revenue from product sales; its 'returns' are measured in therapeutic outcomes and patient impact rather than financial returns.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Solve FSHD product offering
Product offeringCore offering
SOLVE FSHD is a venture philanthropy organization that accelerates the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) by funding and co-developing therapeutic programs. It deploys a competitive academic grant program (up to $300,000 USD per award over two years) and direct strategic investments into biotech and biopharma partners working on DUX4-targeted therapies, biomarkers, natural history studies, and clinical outcome validation. Its product is the funded portfolio of therapeutic programs and the convening infrastructure (FSHD Industry Collaborative, $10M FSHD Bonus Prize via XPRIZE Healthspan) that aims to deliver a cure by December 31, 2027.
Product overview
Solve FSHD is a venture philanthropy organization rather than a traditional product company. The organization functions as a catalytic funding entity that identifies, funds, and accelerates promising therapeutic programs for Facioscapulohumeral Muscular Dystrophy (FSHD). The portfolio consists of strategic investments in external biotech and academic programs including: the MDL-103 CRISPR epigenome editing program (Modalis collaboration), ARM-201 AAV-delivered microRNA therapy (Armatus Bio investment), EPI-321 epigenetic therapy (Epic Bio investment), VTA-120 cell therapy (Vita Therapeutics investment), MC-DX4 antibody-RNA conjugate (miRecule investment), and AI-driven drug screening (Transcripta Bio collaboration). Additionally, the organization operates a grants program supporting biomarker research and clinical outcome validation at academic institutions. The interconnected portfolio is unified by the common goal of developing disease-modifying treatments that target the genetic cause of FSHD (DUX4 gene suppression or muscle regeneration) with a target solve date of December 31, 2027.
Differentiator
Problem solved
Functional benefit
Products and services
- FSHD Research Funding Program Annual competitive grant program offering up to $300,000 USD per award (maximum 10% overhead, up to 2 years) to academic investigators conducting FSHD biomarker discovery, natural history studies, clinical outcome validation, and pre-clinical therapy development. Open to university and research hospital PIs globally.
- XPRIZE Healthspan FSHD Bonus Prize Global $10 million milestone-prize competition co-sponsored by SOLVE FSHD as part of XPRIZE Healthspan, awarding eight $250,000 interim prizes by June 2025 and an $8 million grand prize for teams completing a clinical trial that demonstrates significant FSHD treatment advancements. Open to global teams.
- FSHD Patient Resource Network Curated network connecting FSHD patients and families to patient advocacy organizations (FSHD Society, FSHD Global Research Foundation, FSHD Canada Foundation, MDA) for information, guidance, advocacy, direct support, registry participation, and clinical trial access.
- FSHD Industry Collaborative Multi-stakeholder industry collaborative co-organized by SOLVE FSHD with the FSHD Society and FSHD Clinical Trial Research Network and founding biopharma sponsors Sanofi, Fulcrum Therapeutics, and Scholar Rock to improve FSHD clinical trial design, execution, and evaluation and unify regulatory narratives.
Quantifiable outcome
- Grant funding of ~$571,000 awarded across two projects in 2025 to validate biomarker assays and clinical outcome frameworks for FSHD, with recipients at Radboud University and Newcastle University.
- +3 more outcomes
Companies that use Solve FSHD
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Solve FSHD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Solve FSHD partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core, major and minor.
- FSHD SocietycoreThe FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network jointly launched the FSHD Industry Collaborative, a multi-stakeholder initiative to improve how FSHD clinical trials are designed, executed, and evaluated. The collaborative brings together biopharma companies, academic experts, and technology partners.
- FSHD Clinical Trial Research Network (FSHD CTRN)corePartner in the FSHD Industry Collaborative alongside the FSHD Society and SOLVE FSHD, focused on improving the design, execution, and evaluation of FSHD clinical trials. The CTRN provides clinical research infrastructure and expertise.
- SanoficoreSanofi is a key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative co-organized by the FSHD Society, SOLVE FSHD, and the FSHD CTRN to improve FSHD clinical trial design, execution, and evaluation. Sanofi joins Fulcrum Therapeutics and Scholar Rock as founding industry sponsors.
- Fulcrum TherapeuticscoreFulcrum Therapeutics is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for rare diseases, including FSHD, and participates in the collaborative to help improve clinical trial design and reduce drug development risk.
- Scholar RockcoreScholar Rock is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for serious diseases, including neuromuscular conditions, and participates in the collaborative to improve FSHD clinical trial outcomes.
- Modalis Therapeutics CorporationcoreSOLVE FSHD and Modalis announced a strategic collaboration to develop MDL-103, an innovative CRISPR-based epigenome editing treatment for FSHD using Modalis's proprietary CRISPR-GNDM technology to continuously suppress DUX4 gene expression. SOLVE FSHD provides strategic funding to support the MDL-103 program's advancement toward clinical trials.
- Radboud University Medical Center (Prof. Nicol Voermans)majorProf. Nicol Voermans from Radboud University Medical Center was selected as a grant recipient from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding across two projects to validate biomarker assays and clinical outcome frameworks for FSHD.
- Newcastle University (Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra)majorProf. Dr. Giorgio Tasca and Dr. Robert Muni Lofra from Newcastle University were selected as grant recipients from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding to validate biomarker assays and clinical outcome frameworks for FSHD.
- Transcripta BiomajorSOLVE FSHD entered a strategic collaboration with Transcripta Bio to leverage its AI-driven drug screening platform to identify and develop therapeutic candidates for FSHD. The project analyzes approved and late-stage clinical compound libraries in FSHD cell lines targeting fibro-adipogenic progenitor cells, representing a significant step in drug repurposing for FSHD.
- SOLVE FSHD 2023 Grant Recipients (4 Collaborative Projects)majorSOLVE FSHD awarded grants totaling USD $1.4M to four new collaborative research projects addressing critical gaps in FSHD therapeutics, biology, and/or biomarkers. Recipients represent relationships formed between academic and industry researchers during SOLVE FSHD's inaugural conference in Whistler, British Columbia.
- FSHD Canada FoundationmajorSOLVE FSHD financially supported the FSHD Canada Foundation's strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in FSHD. The collaboration funded four projects including circulating biomarkers (Prof. Enzo Ricci and Dr. Giorgio Tasca), AI analysis for serum biomarkers (IMPROVE FSHD), UNDERSTAND FSHD2 natural history study (Dr. Sabrina Sacconi), and circulating biomarkers (Dr. Yi-Wen Chen).
- FSHD SocietycoreFSHD Society is a key patient advocacy partner in the FSHD Industry Collaborative and a co-organizer of the FSHD Industry Collaborative alongside SOLVE FSHD and the FSHD CTRN. The organization provides information, guidance, advocacy, direct support, and access to clinical trials for the FSHD patient community.
- FSHD Global Research FoundationminorFSHD Global Research Foundation is listed as a partner organization providing information, guidance, advocacy, and direct support to the FSHD patient community. It is part of SOLVE FSHD's patient resource network.
- Michael Kyba (University of Minnesota)majorMichael Kyba serves on SOLVE FSHD's Scientific Advisory Board. He is Carrie Ramey CCRF Endowed Professor of Pediatrics at the University of Minnesota, where he investigates molecular mechanisms underlying DUX4 function and runs an active drug discovery program around DUX4 and FSHD.
- Lawrence Korngut (Calgary Neuromuscular Program)majorLawrence Korngut serves on SOLVE FSHD's Scientific Advisory Board. He is a Neuromuscular Neurologist and former Director of the Calgary Neuromuscular Program and Calgary ALS Clinic. His team has conducted over 90 neuromuscular disease clinical trials and he is National Principal Investigator of the Canadian Neuromuscular Disease Registry.
- Peter Zammit (King's College London)majorPeter Zammit serves on SOLVE FSHD's Scientific Advisory Board. He is Professor of Cell Biology at King's College London and his contributions to FSHD include devising biomarkers (suppression of PAX7 target genes), quantifying muscle regeneration, and defining mitochondrial/metabolic dysfunction in FSHD.
- Giorgio Tasca (Newcastle University)majorGiorgio Tasca serves on SOLVE FSHD's Scientific Advisory Board. He is Clinical Professor of Neuromuscular Science at the John Walton Muscular Dystrophy Research Centre, Newcastle University, UK. His research focuses on muscle imaging in muscular dystrophies and molecular mechanisms and biomarkers in FSHD.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Solve FSHD competitors and assessment
Company assessmentBroad incumbents
- ALS Association: The ALS Association is a large incumbent patient advocacy organization funding ALS research, with biotech partnerships and clinical-trial infrastructure. Broader in scope than Solve FSHD but shares the playbook of combining patient advocacy, research grants, and industry collaboration.
- Muscular Dystrophy Association: MDA is the largest U.S. advocacy and research-funding organization for muscular dystrophy broadly, including FSHD. Larger and more diversified than Solve FSHD, with overlapping mission focus on FSHD research funding and patient support, but covers multiple disease areas.
Direct peers
- FSHD Society: The FSHD Society is the leading FSHD-specific patient advocacy organization and a core partner of Solve FSHD in the FSHD Industry Collaborative. Comparable FSHD focus, but operates primarily as an advocacy/registry/education body rather than a venture philanthropy grantmaker.
- Parent Project Muscular Dystrophy: PPMD is a patient-founded nonprofit focused on Duchenne muscular dystrophy that funds research, drug development, and regulatory engagement — operating with a similar venture philanthropy / advocacy hybrid model on an adjacent muscular dystrophy indication.
- SMA Foundation: Spinal Muscular Atrophy Foundation is a disease-specific venture philanthropy organization funding SMA therapeutics R&D and biomarkers. Solve FSHD board member Karen Chen is SMA Foundation's CEO, highlighting the close operational and strategic parallels between the two organizations.
- Friedreich's Ataxia Research Alliance: FARA is a single-disease research foundation that funds academic and biotech drug development for Friedreich's ataxia using a venture philanthropy model. Closely comparable mission, funding mechanism, and biotech partnership playbook to Solve FSHD.
- n-Lorem Foundation: n-Lorem applies a venture philanthropy model to develop ASO therapies for nano-rare patients, and is itself a Solve FSHD grantee ($1M+ for FSHD2). Direct structural and operational comparison to Solve FSHD's grantmaking + biotech-investment playbook.
- Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation pioneered the venture philanthropy model that Solve FSHD now uses — funding academic research and biotech drug development (including the program that became Vertex's Trikafta) toward curative therapies for a single rare disease. Highly comparable structure, capital deployment strategy, and mission framing.
Regional players
- FSHD Canada Foundation: FSHD Canada Foundation is a Canadian patient organization and Solve FSHD partner that has deployed $1.2M of biomarker grant funding. Similar disease focus but smaller scale and primarily regional (Canada) compared to Solve FSHD's global mandate.
- FSHD Global Research Foundation: FSHD Global is an Australia-based patient advocacy and research-funding organization focused on FSHD. Geographically complementary rather than directly competing with Solve FSHD's Vancouver-based global operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Solve FSHD social profiles
Digital presenceSolve FSHD financial estimates
Financial estimateRevenue estimate
Valuation estimate
Solve FSHD leadership team
Management profileNumber of profiles
Profiles8 records
Solve FSHD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Solve FSHD M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Solve FSHD
What does Solve FSHD do?
SOLVE FSHD is a venture philanthropy organization that accelerates the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) by funding and co-developing therapeutic programs. It deploys a competitive academic grant program (up to $300,000 USD per award over two years) and direct strategic investments into biotech and biopharma partners working on DUX4-targeted therapies, biomarkers, natural history studies, and clinical outcome validation. Its product is the funded portfolio of therapeutic programs and the convening infrastructure (FSHD Industry Collaborative, $10M FSHD Bonus Prize via XPRIZE Healthspan) that aims to deliver a cure by December 31, 2027.
Is Solve FSHD a public or private company?
Solve FSHD is a private company. It is classified as family owned and is currently operating.
When was Solve FSHD founded?
Solve FSHD was founded in 2022. It employs 1 to 10 people.
Where is Solve FSHD based?
Solve FSHD is headquartered in Vancouver, Canada, in the North America region.
How does Solve FSHD make money?
One revenue line is on record: venture Philanthropy / Charitable Grant Funding.
Who are Solve FSHD's main competitors?
Broad incumbents on record are ALS Association and Muscular Dystrophy Association. Direct peers are FSHD Society, Parent Project Muscular Dystrophy, SMA Foundation, Friedreich's Ataxia Research Alliance, n-Lorem Foundation and Cystic Fibrosis Foundation. Regional players are FSHD Canada Foundation and FSHD Global Research Foundation.
Does Solve FSHD have an API?
No public API is recorded for Solve FSHD.
What industry is Solve FSHD in?
Solve FSHD's product category is Venture Philanthropy / FSHD Disease Research Funding. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8731.